Accomplish the highest outcome during development and manufacturing of novel antibodies or equivalents
Capricorn’s supplements and media for hybridoma cell culture perform well in nearly all systems. We support our diagnostic industry partners with a special emphasis on every scale of their process to find the most comfortable solution.
Advantages at a glance
Hybridoma and monoclonal antibodies launched a multi-billion-dollar industry. This technology is based on the fusion of a B-lymphocyte cell and a tumor cell. The result of this fusion is known as a hybridoma, an immortal cell that produces specific antibodies.
Though other platforms have been developed, the hybridoma technology, which has enabled over 45 years of mAb research and even large-scale perfusion culture, is still broadly used. Our products are developed to meet the demands of our diagnostic and biopharmaceutical customers.
HybridomaPlus provides the easiest and safest solution in the production of diverse antibodies with recombinant myeloma lines as well as traditional hybridoma. The ready-to-use medium, HybridomaPlus is animal origin-free, serum-free and protein-free. It is also free of any factors or mediators that may complicate downstream processing and final product purification, thereby facilitating a perfect environment for cell culture.
Developed to meet the needs of biotechnology manufacturing, this medium supports rapid initial cell growth and high levels of antibody expression.
Our Hybridoma Supplement is a growth-promoting supplement containing insulin, ethanolamine, hydrocortisone, retinoic acid, and other factors.
Hybridoma Supplement replaces formerly used feeder cells, thereby eliminating disadvantages such as the overgrowth of newly formed hybridoma, possible contamination, competition for nutrients, and variations in growth factor concentrations.
Our Hybridoma Supplement can be used in culture media under serum-free conditions. The low protein content facilitates the isolation and purification of produced antibodies, thereby improving growth after fusion and the cloning efficiency of hybridoma.